Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.
Hallevi
Hen
H
Grotta
James C
JC
D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002536:Cerebral Arteries / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D018570:Risk Assessment; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator